Same-Visit Chlamydia and Gonorrhea Testing for OB/GYN Practices
Annual well-woman exams are the most consistent chlamydia and gonorrhea screening opportunity in your practice. Send-out testing means many patients never come back for treatment and never get counted toward your screening measures.
Same-Visit Screening, Built for the Well-Woman Visit
The binx io is an FDA-cleared, CLIA-waived, molecular point-of-care platform for chlamydia (CT) and gonorrhea (NG), delivering PCR-accurate results in approximately 30 minutes with no laboratory or lab-trained staff required.1,2,3
Lab Turnaround Times Are Costing You Patients
Send-out testing creates a multi-day window between testing and treatment, during which a significant share of patients never return. POC testing collapses that window to a single visit, directly improving treatment rates and reducing onward transmission.
- 2-3 days of processing time⁶ Patient likely gone before results return
- ~20% lost to follow-up⁴ Patients who never return for treatment or results
- Empiric antibiotic use Treatment decisions often made without confirmed diagnosis, undermining stewardship⁵
- Onward transmission risk Untreated patients continue spreading infection in the community
- ~30 minutes to result Same visit, same provider, same day
- In-visit test results Reducing patients who never return for treatment
- Targeted, confirmed treatment Diagnosis-driven prescribing supports antibiotic stewardship⁵
- Reduced transmission Patients treated in-visit leave with a confirmed result and prescription
Lab-Equivalent Accuracy in a Non-Lab Setting
| Chlamydia Sensitivity / Specificity | Gonorrhea Sensitivity / Specificity | |
|---|---|---|
| Female | 96.1% / 99.1% | 100.0% / 99.9% |
| Male | 92.5% / 99.3% | 97.3% / 100.0% |
It Fits Your Workflow
No lab staff, no certification, no complex setup. Fully automated with clear detected/not detected results, LIS/EMR integration, and an established reimbursement path for CT/NG point-of-care testing.
CLIA- Waived
No laboratory certification required. Any trained staff member can operate the instrument in a point-of-care setting.
Connectable
Ability to route directly into your existing systems. No manual transcription, no extra steps, no lag between result and clinical action.
Established reimbursement
CPT codes for CT/NG point-of-care testing are recognized by Medicare, Medicaid, and most commercial payers.Supports HEDIS Performance⁷
Chlamydia screening is a nationally tracked HEDIS quality measure, based on the percentage of patients ages 16–24 who are sexually active and received at least one chlamydia test during the measurement period.⁷Sources
1. Van Der Pol B, et al. Clinical Performance of the BD ProbeTec™ CT/GC Assay... [2,445-person multicenter study]. JAMA Network Open, 2020. https://doi.org/10.1001/jamanetworkopen.2020.4819 2. binx health io® CT/NG Assay Instructions for Use, MOB-ART-0700 v4.0, May 2022. 3. FDA 510(k) Summary, K191352. https://www.accessdata.fda.gov/cdrh_docs/pdf19/K191352.pdf 4. Schwebke JR, Sadler R, Sutton JM, Hook EW 3rd. Positive screening tests for gonorrhea and chlamydial infection fail to lead consistently to treatment of patients attending a sexually transmitted disease clinic. Sex Transm Dis 1997;24:181-184. https://pubmed.ncbi.nlm.nih.gov/9101628/ 5. Huntington S, Weston G, Adams E. Assessing the clinical impact and resource use of a 30-minute chlamydia and gonorrhoea point-of-care test at three sexual health services. Ther Adv Infect Dis, 2021. https://doi.org/10.1177/20499361211061645 6. Labcorp. Chlamydia/Gonococcus, NAA (Test 183194) — Result Turnaround Time. https://www.labcorp.com/tests/183194/chlamydia-gonococcus-naa 7. NCQA. Chlamydia Screening (CHL) — HEDIS Measure. https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/chlamydia-screening-chl/
